share_log

Bellerophon Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Janus Henderson Group plc(5.1%),Janus Henderson Biotech Innovation Master Fund Ltd(5.1%)

SEC announcement ·  May 25, 2023 23:17
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.